sintilimab combined with anlotinib

DRUG3 trials

Sponsors

Zhejiang Cancer Hospital, Shanghai Chest Hospital, First Affiliated Hospital of Wannan Medical College

Conditions

Anti-angiogenesisImmunotherapyMinimal Residual DiseaseNSCLCNon-small Cell Lung CancerResistance to ImmunotherapySmall Cell Lung Cancer Extensive Stage

Phase 2

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

CompletedNCT04691388

Zhejiang Cancer HospitalNSCLC

Start: 2021-03-01End: 2024-12-01Updated: 2024-12-05

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Shanghai Chest HospitalAnti-angiogenesis, Immunotherapy, Minimal Residual Disease +1

Start: 2022-01-01End: 2024-12-31Target: 42Updated: 2022-07-15

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

Not yet recruitingNCT07022301

First Affiliated Hospital of Wannan Medical CollegeResistance to Immunotherapy, Small Cell Lung Cancer Extensive Stage

Start: 2025-07-31End: 2029-05-31Target: 25Updated: 2025-06-15

Related Papers

An Open‐Label, Single‐Arm, Phase <scp>II</scp> Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line <scp>PD</scp> ‐(L)1 Inhibitor

Cancer Medicine2025-09-012 citations